EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

被引：0
|
作者：
Martin, M. [1 ]
Eiermann, W. [2 ]
Rugo, H. S. [3 ]
Ettl, J. [4 ]
Hurvitz, S. A. [5 ]
Goncalves, A. [6 ]
Yerushalmi, R. [7 ]
Markova, D. [8 ]
Tudor, I. C. [8 ]
Blum, J. L. [9 ]
Hannah, A. L. [10 ]
Litton, J. K. [11 ]
机构：
[1] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Med Oncol, CIBERONC,GEICAM, Madrid, Spain
[2] Interdisziplinares Onkol Zentrum Munchen, Chest Surg, Munich, Germany
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[4] Tech Univ Munich, Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
[5] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[6] Inst Paoli Calmettes, Med Oncol, Marseille, France
[7] Beilinson Med Ctr, Rabin Med Ctr, Med Oncol, Petah Tiqwa, Israel
[8] Pfizer Inc, Biostat, San Francisco, CA USA
[9] Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[10] Pfizer Inc, Med Oncol, San Francisco, CA USA
[11] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
303P
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis
    Goncalves, A.
    Eiermann, W.
    Rugo, H. S.
    Ettl, J.
    Hurvitz, S. A.
    Yerushalmi, R.
    Martin, M.
    Al-Adhami, M.
    Tudor, I. C.
    Blum, J. L.
    Hannah, A. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis
    Mina, L.
    Lee, K-H
    Goncalves, A.
    Woodward, N.
    Hurvitz, S. A.
    Diab, S.
    Yerushalmi, R.
    Goodwin, A.
    Moreira Costa Zorzetto, M.
    Kim, S-B
    Czibere, A.
    Tudor, I. C.
    Gauthier, E.
    Litton, J. K.
    Ettl, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.
    Diab, Sami
    Rugo, Hope S.
    Mina, Lida A.
    Puhalla, Shannon
    Mahtani, Reshma L.
    Henry, Norah Lynn
    Denduluri, Neelima
    Yardley, Denise A.
    Wang, Yao
    Arruda, Lillian Shahied
    Tudor, Iulia Cristina
    Gauthier, Eric Roland
    Czibere, Akos Gabor
    Litton, Jennifer Keating
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
    Rugo, H. S.
    Niyazov, A.
    Bhattacharyya, H.
    Arondekar, B.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S480 - S480
  • [5] Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial
    Ettl, Johannes
    Hurvitz, Sara A.
    Rugo, Hope S.
    Lee, Kyung-Hun
    Mina, Lida A.
    Woodward, Natasha E.
    Yerushalmi, Rinat
    Diab, Sami
    Martin, Miguel
    Tudor, Iulia Cristina
    Czibere, Akos Gabor
    Gauthier, Eric Roland
    Litton, Jennifer Keating
    Goncalves, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
    Rugo, H. S.
    Quek, R.
    Ettl, J.
    Hurvitz, S. A.
    Bhattacharyya, H.
    Hannah, A. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY TREATMENT (PCT): A FOCUS ON THE EMBRACA HR+/HER2-SUBPOPULATION
    Hurvitz, Sara A.
    Quek, Ruben G. W.
    Ettl, Johannes
    Rugo, Hope
    Bhattacharyya, Helen
    Hannah, Alison L.
    Litton, Jennifer Keating
    BREAST, 2018, 41 : S27 - S28
  • [8] Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/without visceral disease
    Ettl, J.
    Quek, R. G. W.
    Bhattacharyya, H.
    Rugo, H. S.
    Hurvitz, S. A.
    Goncalves, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 129 - +
  • [9] PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS
    Quek, R. G. W.
    Bhattacharyya, H.
    Goncalves, A.
    Rugo, H. S.
    Hurvitz, S. A.
    Ettl, J.
    VALUE IN HEALTH, 2019, 22 : S532 - S532
  • [10] Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician's choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
    Martin, M.
    Rugo, H. S.
    Hurvitz, S. A.
    Ettl, J.
    Roche, H.
    Lee, K-H.
    Goodwin, A.
    Usari, T.
    Lanzalone, S.
    Guenzel, C. A.
    Blum, J.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S481 - S481
12345